Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Generic Versions Of Focalin Clear FDA With 180-Day Exclusivity

This article was originally published in The Pink Sheet Daily

Executive Summary

The approval includes 2.5 mg, 5 mg and 10 mg formulations of dexmethylphenidate tabs for ADHD.

You may also be interested in...



Novartis Files Suit To Block Barr From Marketing Generic Ritalin LA

Barr’s ANDA with Paragraph IV certification was accepted by FDA in September, generics firm says.

Novartis Files Suit To Block Barr From Marketing Generic Ritalin LA

Barr’s ANDA with Paragraph IV certification was accepted by FDA in September, generics firm says.

Shire Anticipates Vyvanse Approval In “Next Month Or Two”

The firm is considering a marketing partner and aims to replace its ADHD treatment Adderall XR with Vyvanse.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS065114

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel